BTIG analyst David Larsen raised the firm’s price target on Veeva (VEEV) to $335 from $280 and keeps a Buy rating on the shares after its Q1 earnings beat and guidance raise. Heading into the quarter, the firm was worried about a slowdown in sales given the risk of pharma tariffs, government agency changes, drug pricing reform efforts, the Inflation Reduction Act, global conflicts, and other macro worries, but Veeva is not seeing any slowdown, growth in both Commercial and R&D were excellent, and BTIG remains positive on the company capturing more market share, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva price target raised to $295 from $272 at Stifel
- Veeva price target raised to $300 from $285 at Wells Fargo
- Veeva Systems’ Strong Q1 Performance and Raised Outlook Signal Promising Growth Amid CRM Transition Challenges
- Veeva price target raised to $325 from $255 at Piper Sandler
- Cautious Hold on Veeva Systems Amid CRM Challenges and Valuation Concerns